Solid Biosciences Inc. (SLDB) - A Look Into the Future of Gene Therapy for Neuromuscular and Cardiac Diseases

Solid Biosciences Inc. (SLDB) is positioning itself as an emerging biotechnology company focused on developing precise gene therapies for rare neuromuscular and cardiac diseases. The company has a diversified pipeline aimed at indications with high unmet needs. At the forefront is SGT-003, a next-generation gene therapy for Duchenne muscular dystrophy (DMD). The ongoing Phase 1/2 study INSPIRE DUCHENNE shows promising initial data with robust micro-dystrophin expression and improvements in biomarkers of muscle integrity as well as heart and liver...